Investigating biomarkers for heart transplant rejection
Biomarkers for Diagnosis, Prognosis, and Targeted Therapy After Heart Transplantation
This study is testing if certain blood markers can help doctors better detect and predict heart transplant rejection in patients who have received a heart transplant.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Helsinki University Central Hospital Academic / other |
| Locations | 1 site (Helsinki, Uusimaa) |
| Trial ID | NCT06064123 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the use of donor-derived cell-free DNA and various mRNA expressions in blood samples to identify biomarkers for diagnosing and predicting heart transplant rejection. By analyzing these biomarkers, the study seeks to improve targeted therapies for conditions such as primary graft failure and acute rejection. The research will involve heart transplant recipients and will focus on developing liquid biopsies for better monitoring of their condition post-transplant.
Who should consider this trial
Good fit: Ideal candidates for this study are adult heart transplant recipients who have provided informed consent.
Not a fit: Patients who are not heart transplant recipients or those who cannot provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate and timely diagnosis and treatment of heart transplant rejection, improving patient outcomes.
How similar studies have performed: Other studies have shown promise in using liquid biopsies and biomarkers for monitoring transplant rejection, indicating a potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * patient age \> 18 years * heart transplant recipient * has signed informed consent Exclusion Criteria: * foreign residency * no signed informed consent collected
Where this trial is running
Helsinki, Uusimaa
- Helsinki University Hospital — Helsinki, Uusimaa, Finland (Recruiting)
Study contacts
- Principal investigator: Karl B Lemström, MD, PhD — Helsinki University Central Hospital
- Study coordinator: Karl B Lemstrom, MD, PhD
- Email: Karl.Lemstrom@Hus.Fi
- Phone: +358504272281
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.